A phase I open label study to asses the safety and tolerability of ZD6474 [vandetanib] in combination with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) as first or second line therapy in patients with metastatic colorectal adenocarcinoma

Trial Profile

A phase I open label study to asses the safety and tolerability of ZD6474 [vandetanib] in combination with irinotecan, 5-fluorouracil and leucovorin (FOLFIRI) as first or second line therapy in patients with metastatic colorectal adenocarcinoma

Completed
Phase of Trial: Phase I

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Vandetanib (Primary) ; Fluorouracil; Folinic acid; Irinotecan
  • Indications Colorectal cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 08 Apr 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 08 Apr 2009 Patient number (22) and study completion date (June 2008) as reported by ClinicalTrials.gov record.
    • 16 Nov 2008 Planned end date changed from Mar 2008 to Nov 2008 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top